-
Media Release
Novartis provides update on delpacibart etedesiran (del-desiran) Phase III HARBOR study for the treatment of myotonic dystrophy type 1 (DM1)
-
Media Release
Novartis announces Lp(a)HORIZON Phase III topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD)
-
Media Release
Novartis remibrutinib, a high-efficacy oral BTK inhibitor, significantly reduces relapse rates and shows favorable safety profile in Phase III RMS trials
-
Media Release
Novartis data at ESC Congress 2026 reinforce cardiovascular leadership and showcase progress in next-generation therapies
-
Story
Novartis marks 30 years of breakthroughs, building on 250 years of discovery to reimagine what medicine can do next -
Media Release
FDA approves Pluvicto® for PSMA+ metastatic hormone-sensitive prostate cancer (mHSPC), advancing potential new standard of care across metastatic disease
-
Media Release
Novartis Fabhalta® (iptacopan) receives FDA traditional approval as first and only complement inhibitor to significantly slow kidney function decline in primary IgAN
-
Story
The Future of Autoimmune Disease: A Q&A You Need to Read -
Media Release
Novartis RemIND data at EAACI show Rhapsido® potential as first targeted therapy for chronic inducible urticaria (CIndU)
-
Media Release
Novartis to highlight Rhapsido® data across multiple immune-mediated diseases at EAACI Congress 2026
-
Media Release
Novartis IgAN data in The Lancet show clinically meaningful slowing of kidney function decline with Vanrafia® over 2.5 years
-
Media Release
Novartis Cosentyx® PMR data in New England Journal of Medicine showed sustained remission vs placebo in twice as many patients